Titan Pharmaceuticals Inc financial data

Symbol
TTNP on Nasdaq, TTNPW on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
400 Oyster Point Blvd, Suite 505, San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 438 % +138%
Quick Ratio 11.2 % +24%
Debt-to-equity 28.8 % -72%
Return On Equity -99.9 % +72.5%
Return On Assets -77.6 % +56.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 914 K shares -93.9%
Common Stock, Shares, Outstanding 914 K shares -93.9%
Entity Public Float 7.3 M USD -71.5%
Weighted Average Number of Shares Outstanding, Basic 853 K shares +13.6%
Weighted Average Number of Shares Outstanding, Diluted 853 K shares +13.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.91 M USD -59.8%
General and Administrative Expense 5.38 M USD -9.57%
Costs and Expenses 2.47 M USD -9.75%
Operating Income (Loss) -6.64 M USD +29.3%
Nonoperating Income (Expense) 1.69 M USD +3148%
Income Tax Expense (Benefit) 1 K USD
Net Income (Loss) Attributable to Parent -4.95 M USD +47%
Earnings Per Share, Basic -6.42 USD/shares +44.4%
Earnings Per Share, Diluted -6.42 USD/shares +62.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.16 M USD +442%
Accounts Receivable, after Allowance for Credit Loss, Current 134 K USD +1575%
Inventory, Net 0 USD -100%
Assets, Current 6.61 M USD +270%
Property, Plant and Equipment, Net 3 K USD -98.3%
Operating Lease, Right-of-Use Asset 32 K USD -79.2%
Other Assets, Noncurrent 48 K USD 0%
Assets 6.65 M USD +207%
Accounts Payable, Current 371 K USD -34.6%
Liabilities, Current 559 K USD -77.2%
Operating Lease, Liability, Noncurrent 33 K USD -79.1%
Liabilities 559 K USD -77.5%
Retained Earnings (Accumulated Deficit) -393 M USD -1.28%
Stockholders' Equity Attributable to Parent 6.09 M USD
Liabilities and Equity 6.65 M USD +207%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -613 K USD +67.7%
Net Cash Provided by (Used in) Financing Activities 10 M USD +101%
Net Cash Provided by (Used in) Investing Activities 732 K USD
Common Stock, Shares Authorized 225 M shares 0%
Common Stock, Shares, Issued 914 K shares -93.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.16 M USD +399%
Interest Paid, Excluding Capitalized Interest, Operating Activities 13 K USD
Deferred Tax Assets, Valuation Allowance 65 M USD -7.55%
Deferred Tax Assets, Gross 65 M USD -7.58%
Operating Lease, Liability 33 K USD -79.1%
Payments to Acquire Property, Plant, and Equipment 2 K USD
Lessee, Operating Lease, Liability, to be Paid 33 K USD -79.9%
Property, Plant and Equipment, Gross 711 K USD -60.9%
Operating Lease, Liability, Current 33 K USD -73.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 66 K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 33 K USD -66.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1 K USD -88.9%
Deferred Tax Assets, Operating Loss Carryforwards 53.2 M USD -8.07%
Preferred Stock, Shares Issued 950 K shares
Preferred Stock, Shares Authorized 5 M shares
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 399 M USD +2.93%
Preferred Stock, Shares Outstanding 950 K shares
Depreciation, Depletion and Amortization 2 K USD -95.3%
Share-based Payment Arrangement, Expense 1.01 M USD +6.97%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares